Storm clinches $56m in Series C for Phase II on lead sarcoma drug
The Pfizer-backed Series C round will see Storm work out an accelerated approval pathway for STC-15 in sarcoma.
Therapy Area
PDS Biotech’s stock up on colorectal cancer trial success
Lilly’s Jaypirca racks up fourth Phase III CLL win
Never-married individuals reported to have higher cancer risk
AbbVie’s Elahere succeeds in Phase II platinum-sensitive ovarian cancer trial
BioNTech and DualityBio report positive data for trastuzumab pamirtecan
Verastem Oncology’s combo shows two-year durability in ovarian cancer
Smartwatches could aid in monitoring heart failure exacerbations
